GlassScriptPhysician profile
Tiffany M Lee
NPI 1215307202
$2,429.80
in general payments reported to CMS, 2019-2025
25 companies · $834 in 2025
The $834 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $220 · 2023: $346 · 2024: $398 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542 · Education: $35.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.52 |
| Education | $35.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $333.51 | 2021-2023 | Velphoro |
| Akebia Therapeutics INC | $250.06 | 2021-2025 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $226.10 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $176.58 | 2021-2024 | Farxiga, Brilinta |
| Vifor Pharma, INC. | $170.13 | 2021-2024 | Veltassa |
| Travere Therapeutics, INC. | $166.40 | 2024-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $155.00 | 2024-2025 | |
| Nxstage Medical, INC. | $135.19 | 2023 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $114.41 | 2021-2025 | Krystexxa, Tavneos |
| Xeris Pharmaceuticals, INC. | $106.66 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $82.98 | 2021-2025 | Jynarque |
| Horizon Therapeutics Plc | $67.69 | 2021-2022 | |
| Glaxosmithkline, LLC. | $61.50 | 2023-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $58.58 | 2022-2025 | Acthar |
| Novo Nordisk INC | $57.32 | 2021-2025 | Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $53.93 | 2024-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $49.87 | 2021-2025 | Rayaldee |
| Merck Sharp & Dohme LLC | $28.79 | 2021 | |
| Aurinia Pharma U.S., INC. | $26.60 | 2021-2024 | Lupkynis |
| Mannkind Corporation | $25.19 | 2025 | |
| Baxter Healthcare | $21.69 | 2024 | Renal - Chronic |
| Ardelyx, INC. | $17.17 | 2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $17.14 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.68 | 2025 | Jardiance |
| Lilly USA, LLC | $13.63 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.